<DOC>
	<DOCNO>NCT01766960</DOCNO>
	<brief_summary>One-third U.S. population suffers non-alcoholic fatty liver disease ( NAFLD ) . NAFLD cause diabetes obesity , become common . Although many people disease , change liver handle drug compound body study . The purpose study investigate advance NAFLD change ability liver handle endogenous exogenous compound .</brief_summary>
	<brief_title>Altered Drug Disposition Biomarkers Diagnosis Chronic Inflammatory Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>General : Man woman 18 65 year age Negative pregnancy test woman childbearing potential Negative urine drug screen Healthy Subjects : Normal liver function test Normal kidney function lipid panel Nonalcoholic Steatohepatitis Patients : Recent liver biopsy nonalcoholic fatty liver disease activity score least 4 General : History significant alcohol use ( &gt; 20 g/day ) and/or illicit drug use Inability abstain alcohol 48 prior study Use drug associate clinical histological picture consistent fatty liver disease NASH 12 consecutive week year prior screening ; include amiodarone , tamoxifen , methotrexate , glucocorticoid , anabolic steroid , tetracycline , estrogen ( dos great use hormone replacement ) valproate/valproic acid Type 2 diabetes treat oral agent metformin ; include secretagogues , thiazolidinediones , alphaglucosidase inhibitor , exenatide pramlintide . Current recent use bile acid sequestrants , bile acid derivative ( i.e . ursodiol ) fibric acid derivative . Current use antioxidant silymarin , vitamin C , glutathione , nonprescribed complementary alternative medication ( include dietary supplement , megadose vitamin , herbal preparation , special tea ) within 30 day prior screen . Previous liver biopsy demonstrate presence cirrhosis . Radiologic image consistent cirrhosis portal hypertension . Serum creatinine 2.0 mg/dL great , dialysis , screen . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , severe psoriasis , rheumatoid arthritis ) could affect assessment biomarkers ( bile acid inflammation ) . History bariatric surgery . BMI &gt; 45 kg/m^2 screening . Any known hypersensitivity opiate , opiate antagonist , ondansetron . Healthy Subjects : Taking concomitant medication , prescription nonprescription ( include herbal product overthecounter medication ) , oral contraceptive multivitamin ( woman stabilize hormonal method birth control allow participate ) History evidence liver disease opinion study investigator . BMI &gt; 30 kg/m^2 screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bile acid</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>